Bioverativ and Invicro form imaging collaboration to improve joint disease management in hemophilia Aug. 25, 2017
Participant enrollment underway in phase II trial of concizumab in hemophilia A and B patients Aug. 21, 2017
Portola Pharmaceuticals is assigned a PDUFA date for the factor Xa inhibitor antidote andexanet Aug. 16, 2017
Zelboraf granted priority review and breakthrough therapy designation for Erdheim-Chester disease Aug. 8, 2017
RSS